SoluMatrix meloxicam regulatory update

FDA accepted for review an NDA for Iroko’s SoluMatrix meloxicam to treat osteoarthritis pain. Iroko declined to disclose the PDUFA date. The product is a low-dose formulation of the NSAID meloxicam th...